胰高血糖素样肽-1受体激动剂对高危哮喘和肥胖患者哮喘控制的真实世界影响
The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity.
作者信息
Kaplan Alan, Heatley Heath, Townend John, Skinner Derek, Carter Victoria, Hubbard Richard, Lee Tan Tze, Koh Mariko Siyue, Price David
机构信息
Family Physician Airways Group of Canada, Stouffville, ON, Canada.
Observational and Pragmatic Research Institute, Singapore, Singapore.
出版信息
Adv Ther. 2025 Jun;42(6):2950-2956. doi: 10.1007/s12325-025-03175-x. Epub 2025 Apr 8.
To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90-2.36) and OAC (OR 2.10, 95%CI 1.81-2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.
为了量化胰高血糖素样肽1受体激动剂（GLP1 - RAs）对哮喘控制的影响，我们使用最佳患者护理研究数据库（OPCRD）对哮喘合并肥胖患者进行了分析。我们确定了10111名使用GLP1 - RAs的患者和50555名未使用的对照者。使用GLP1 - RAs的队列具有更高的体重指数和更多未得到控制的哮喘[风险领域哮喘控制（RDAC）和总体哮喘控制（OAC）]。使用GLP1 - RAs的队列体重减轻更多，并且在RDAC（优势比2.11，95%置信区间1.90 - 2.36）和OAC（优势比2.10，95%置信区间1.81 - 2.45）评分方面哮喘控制得到改善。GLP1 - RAs药物似乎能改善肥胖患者的哮喘控制。
Zotero 插件